NPPB and Obesity: Of clinical relevance, stratified analysis by preserved versus reduced left ventricular ejection fraction, NT-proBNP in- and outside the reference range, presence of congestive heart failure, of obesity or left ventricular hypertrophy, levels of eGFR, HbA1c and uric acid demonstrated consistency and robustness of the effect of empagliflozin 10 mg/day compared with placebo on left ventricular E/e ́ ratio across subgroups.